Management of Acquired Long QT Syndrome in Adults

QT Interval Assessment

Measure the QT interval from the onset of the QRS complex to the point where the tangent of the T‑wave downslope intersects the baseline, preferably using lead II or V5. 1
Upper normal QTc values are < 450 ms in men and < 460 ms in women; a QTc ≥ 480 ms is considered abnormal, and a QTc ≥ 500 ms markedly increases the risk of torsades de pointes (TdP). 1

Differentiating Acquired from Congenital LQTS

Congenital LQTS usually presents earlier in life with syncope triggered by exercise, swimming, or loud noises, and often a family history of sudden death. 1
Acquired LQTS is caused by QT‑prolonging medications, electrolyte disturbances (low potassium, magnesium, or calcium), or underlying structural heart disease. [1][2]

Medication Review and Discontinuation

Perform a comprehensive medication review (e.g., via crediblemeds.org) to identify QT‑prolonging agents such as certain antibiotics (fluoroquinolones, macrolides), antipsychotics, antidepressants (citalopram, escitalopram), antiemetics, and analgesics. [1][3]
Immediately discontinue any QT‑prolonging drug when QTc ≥ 500 ms; if QTc < 500 ms and there is no syncope, continuation may be considered only with close monitoring and if the drug is essential. 3
High‑risk QT‑prolonging drugs include citalopram, escitalopram, ciprofloxacin, and erythromycin; lower‑risk agents include sertraline, azithromycin, cephalosporins, and penicillins. 1

Electrolyte Management

Correct serum potassium to > 4.0 mEq/L, magnesium to > 2.0 mg/dL, and normalize calcium levels. [1][2]
Electrolyte abnormalities are a leading cause of acquired LQTS and must be corrected before attributing QT prolongation to other factors. 1

Cardiac Imaging

Obtain an urgent transthoracic echocardiogram to evaluate left‑ventricular systolic function, left‑atrial size, and valvular disease, which helps identify structural contributors to QT prolongation. 1

Arrhythmia Risk Stratification and Monitoring

If QTc remains ≥ 500 ms after medication and electrolyte optimization, the patient is at high risk for TdP and requires continuous cardiac monitoring. 1
Avoid amiodarone and procainamide, as they further prolong the QT interval and are contraindicated in LQTS‑related arrhythmias. 2
Should TdP occur, treat with intravenous magnesium (even if serum magnesium is normal), correct any bradycardia, and discontinue all QT‑prolonging drugs. 2

When to Consider Congenital LQTS

Evaluate for congenital LQTS if there is a history of unexplained syncope with exercise, swimming, or loud noises, a family history of sudden unexplained death, or if QTc stays > 480 ms after all acquired causes have been eliminated. 1
Referral to an inherited arrhythmia clinic is recommended for suspected congenital LQTS. 4
Exercise testing may reveal abnormal QTc prolongation during recovery (≈ 4 minutes post‑exercise), a characteristic finding of congenital LQTS. 4
Genetic testing for LQTS types 1‑3 can be considered, but clinical phenotyping should precede genetic evaluation. 4

Definitive Treatment of Acquired LQTS

Permanently discontinue QT‑prolonging medications and substitute safer alternatives (e.g., sertraline for depression, azithromycin for infection). [1][3]
Maintain normal electrolyte levels indefinitely, with regular monitoring in patients prone to disturbances (e.g., those on diuretics). [1][2]
Beta‑blockers are not routinely indicated for acquired LQTS unless there is another clinical indication such as heart failure or coronary disease. 2

Management of Confirmed Congenital LQTS (If Identified)

Nadolol is the preferred beta‑blocker for high‑risk patients (QTc ≥ 500 ms, prior syncope, or cardiac arrest), dosed at 1–1.5 mg/kg once daily. [3][4]
Bisoprolol may be used for lower‑risk patients (QTc < 500 ms, no prior events) due to better tolerability. [3][4]
Lifelong avoidance of QT‑prolonging medications is essential, even when beta‑blocker therapy is in place. [3][4]

Key Clinical Pitfalls to Avoid

Do not assume QS complexes in V1‑V2 represent septal infarction without imaging confirmation.
Do not overlook medication‑induced QT prolongation; many commonly prescribed drugs can lengthen the QT interval. [1][3]
Do not use amiodarone or procainamide for ventricular arrhythmias in the setting of prolonged QT, as they exacerbate the problem. 2
Do not diagnose congenital LQTS without first excluding all acquired causes, especially in patients over 50 years old. 1
Re‑check the ECG after medication washout and electrolyte correction; normalization of QTc confirms an acquired etiology and obviates the need for genetic testing. 3

Immediate Management of Prolonged QT Interval

Initial Actions

Discontinue all QT‑prolonging medications, correct potassium to > 4.0 mmol/L and magnesium to > 2.0 mg/dL, and start continuous cardiac monitoring when QTc ≥ 500 ms. – Canadian Cardiology Society [5][6]

Medication Review and Substitution

Perform an urgent comprehensive medication review using crediblemeds.org to identify QT‑prolonging agents. – Canadian Cardiology Society [5][7]
Immediately stop high‑risk drugs, including:
- Antibiotics – macrolides (e.g., erythromycin) and fluoroquinolones (e.g., ciprofloxacin) – Canadian Cardiology Society 5
- Antidepressants/antipsychotics – citalopram, escitalopram, haloperidol, chlorpromazine – Canadian Cardiology Society 5
- Antiarrhythmics – sotalol, dofetilide, amiodarone, procainamide – Canadian Cardiology Society 7
- Antiemetics – ondansetron, droperidol – Canadian Cardiology Society 6
- Analgesics – methadone – Canadian Cardiology Society 6
- Miscellaneous – chloroquine, hydroxychloroquine – Canadian Cardiology Society 5
When possible, substitute safer alternatives:
- Use penicillins or cephalosporins instead of macrolides/fluoroquinolones – Canadian Cardiology Society 5
- Use sertraline or paroxetine instead of citalopram/escitalopram – Canadian Cardiology Society 5

Electrolyte Management

Measure and correct electrolytes immediately, targeting potassium > 4.0 mmol/L (optimally 4.5–5.0 mmol/L) and magnesium > 2.0 mg/dL; normalize calcium if abnormal. – Canadian Cardiology Society [5][6]
Monitor electrolytes closely in patients receiving diuretics or with renal impairment. – Canadian Cardiology Society [5][7]

Risk Stratification and Monitoring

QTc ≥ 500 ms or an increase > 60–70 ms from baseline defines high risk for torsades de pointes (TdP); initiate continuous telemetry and consider ICU admission. – Canadian Cardiology Society [5][7]
High‑risk patient factors that warrant more aggressive monitoring: female sex, advanced age, and underlying structural heart disease. – Canadian Cardiology Society [5][7]

Cardiac Imaging

Obtain an urgent transthoracic echocardiogram to assess left‑ventricular systolic function, left‑atrial size, valvular disease, and other structural abnormalities that may increase arrhythmia risk. – Canadian Cardiology Society [6][7]

Diagnostic Pathway After Intervention

If QTc normalizes after drug removal and electrolyte correction:
- Diagnose acquired long‑QT syndrome (aLQTS); genetic testing is not required.
- Implement permanent avoidance of QT‑prolonging drugs and schedule regular electrolyte monitoring, especially for patients on diuretics. – Canadian Cardiology Society [5][6]7
If QTc remains > 480 ms despite correction:
- Suspect congenital long‑QT syndrome (cLQTS) and refer to an inherited arrhythmia/cardiogenetics clinic.
- Perform an exercise stress test to look for abnormal QTc prolongation post‑exercise.
- Consider genetic testing for KCNQ1, KCNH2, and SCN5A mutations.
- Screen first‑degree relatives with ECG and clinical evaluation. – Canadian Cardiology Society [5][6]8

Management of Confirmed Congenital LQTS

High‑risk patients (QTc ≥ 500 ms or prior syncope/cardiac arrest): prescribe nadolol 1–1.5 mg/kg once daily. – Canadian Cardiology Society 8
Lower‑risk patients (QTc < 500 ms, no prior events): bisoprolol may be used for better tolerability. – Canadian Cardiology Society 8
Lifelong avoidance of all QT‑prolonging medications is required, even when on beta‑blocker therapy. – Canadian Cardiology Society 8

Common Pitfalls to Avoid

Do not overlook medication‑induced QT prolongation; many routinely prescribed drugs have this effect. – Canadian Cardiology Society 7
Do not assume all SSRIs carry equal risk; citalopram/escitalopram have the highest QT‑prolonging potential, whereas sertraline and paroxetine are essentially negligible. – Canadian Cardiology Society [5][7]
Always repeat the ECG after medication washout and electrolyte correction; normalization confirms an acquired etiology. – Canadian Cardiology Society 5
Never add multiple QT‑prolonging agents without checking interactions on crediblemeds.org. – Canadian Cardiology Society [5][6]7
In patients on diuretics, hypokalemia and hypomagnesemia are the most common electrolyte contributors to aLQTS; they must be promptly identified and corrected. – Canadian Cardiology Society [5][6]7

Guidelines for Management of Prolonged QTc Interval (Canadian Cardiovascular Society)

Risk Stratification

A QTc ≥ 500 ms signifies a markedly increased risk of torsades de pointes (TdP) and mandates urgent intervention. [CCS] 9, 10, 11
An increase in QTc > 60–70 ms from baseline, especially when rapid, identifies high‑risk patients. [CCS] 9, 10, 11
Female sex, advanced age, and underlying structural heart disease substantially amplify the risk of QT‑related arrhythmias. [CCS] 10, 11

Immediate Management of QTc ≥ 500 ms or Symptomatic Patients

Discontinue all QT‑prolonging medications immediately. [CCS] 10, 11
Initiate continuous cardiac telemetry (consider ICU admission) and correct electrolytes urgently (K⁺ > 4.0 mmol/L, optimally 4.5–5.0 mmol/L; Mg²⁺ > 2.0 mg/dL; normalize calcium). [CCS] 9, 10, 11
If TdP occurs, give IV magnesium regardless of serum level, correct bradycardia, and avoid amiodarone or procainamide. [CCS] 9, 10, 11

Medication Review and Substitution

Perform a comprehensive drug review using crediblemeds.org to identify all QT‑prolonging agents. [CCS] 9, 11
High‑risk drug classes include macrolide and fluoroquinolone antibiotics, antifungals, antiarrhythmics, antipsychotics/antidepressants, antiemetics, and certain analgesics (e.g., methadone, triptans, chloroquine). [CCS] 9, 11
Intraclass differences: erythromycin carries the highest macrolide risk, azithromycin the lowest; citalopram/escitalopram have the greatest SSRI‑related QT risk, whereas sertraline and paroxetine are essentially negligible. [CCS] 9, 10, 11
Antibiotic substitution: replace macrolides/fluoroquinolones with penicillins or cephalosporins; note that all fluoroquinolones retain QT risk. [CCS] 9, 10, 11
Antidepressant substitution: replace citalopram/escitalopram with sertraline or paroxetine. [CCS] 9, 10, 11
Antipsychotic substitution: avoid ziprasidone, iloperidone, asenapine, and amisulpride; prefer aripiprazole, clozapine, or lurasidone. [CCS] 10
Antiemetic substitution: replace ondansetron or droperidol with aprepitant or dexamethasone. [CCS] 10

Electrolyte Management

Measure and correct potassium to > 4.0 mmol/L (optimally 4.5–5.0 mmol/L) and magnesium to > 2.0 mg/dL; normalize calcium as needed. [CCS] 9, 10, 11
Closely monitor electrolytes in patients on diuretics or with renal impairment, as these are the most common contributors to acquired LQTS. [CCS] 9, 11

ECG Monitoring Recommendations

Pre‑initiation ECG is required when any of the following are present: severe electrolyte disturbance; concurrent use of another QT‑prolonging drug; initiation of high‑risk agents (methadone, sotalol, dofetilide); or multiple risk factors (e.g., diuretic + sotalol). [CCS] 9, 10, 11
Routine ECG is not needed for a healthy individual starting a low‑risk SSRI such as sertraline without additional risk factors. [CCS] 9, 11
Follow‑up ECG should be performed after each dose change of high‑risk drugs (e.g., methadone) and when a second QT‑prolonging agent is added. [CCS] 9, 11

Distinguishing Acquired from Congenital LQTS

Suspect congenital LQTS if QTc remains > 480 ms after discontinuation of all QT‑prolonging drugs and correction of electrolytes. [CCS] 9, 11, 12
Additional red flags for congenital LQTS: unexplained syncope triggered by exercise, swimming, or loud noises; family history of sudden unexplained death or LQTS; presentation at a young age with genotype‑specific triggers. [CCS] 12
If congenital LQTS is suspected, refer the patient to an inherited arrhythmia/cardiogenetics clinic. [CCS] 12
When acquired LQTS is confirmed (QTc normalizes after intervention), genetic testing is unnecessary, but permanent avoidance of QT‑prolonging drugs and regular electrolyte monitoring (especially in diuretic users) are required. [CCS] 9, 11

Management of Confirmed Congenital LQTS

High‑risk patients (QTc ≥ 500 ms or prior syncope/cardiac arrest): initiate nadolol 1–1.5 mg/kg once daily (preferred beta‑blocker) and enforce lifelong avoidance of all QT‑prolonging medications. [CCS] 12
Lower‑risk patients (QTc < 500 ms, no prior events): bisoprolol may be used for better tolerability; strict avoidance of QT‑prolonging drugs remains essential. [CCS] 12
Beta‑blockers provide arrhythmia‑preventive benefit without substantially shortening the QT interval at heart rates of 60–100 bpm. [CCS] 12

Special Populations and Ongoing Monitoring

Women, elderly patients, and those with structural heart disease have higher susceptibility to QT prolongation and should receive intensified surveillance. [CCS] 10, 11
Patients on diuretics or with impaired renal function require regular monitoring of electrolytes, renal function, and ECG due to heightened risk of hypokalemia/hypomagnesemia and drug accumulation. [CCS] 9, 10, 11

Critical Pitfalls to Avoid

Do not assume all SSRIs have equivalent QT risk; citalopram/escitalopram pose the greatest risk, whereas sertraline/paroxetine are negligible. [CCS] 9, 10, 11
Do not overlook medication‑induced QT prolongation; common “innocuous” agents such as macrolides and fluoroquinolones can be culprits. [CCS] 12
Always repeat ECG after drug washout and electrolyte correction; normalization confirms an acquired etiology and obviates the need for genetic testing. [CCS] 9, 11
Never add multiple QT‑prolonging agents without checking for interactions on crediblemeds.org. [CCS] 9, 11
Monitor renal function regularly, as many QT‑prolonging drugs (e.g., ciprofloxacin, fluconazole, sotalol) accumulate in renal disease and may require dose reduction. [CCS] 10

Cardiac Safety Guidelines for the Fluoxetine + Trazodone Combination

1. QT‑Prolongation Risk Profiles of the Individual Drugs

Brexpiprazole, aripiprazole, and lurasidone have negligible QT‑prolongation risk, whereas ziprasidone, iloperidone, and amisulpride carry the highest risk among atypical antipsychotics (low‑quality evidence from randomized trials and systematic reviews) [13][14]
Fluoxetine occupies an intermediate position with low but non‑zero QT risk; citalopram and escitalopram have the highest QT risk among SSRIs, while paroxetine and sertraline have negligible risk [13][14]

2. Guideline Recommendations (Canadian Cardiovascular Society, 2023)

An ECG must be obtained before starting any QT‑prolonging drug when the patient is already receiving another QT‑prolonging agent (Class I recommendation) [13][14]
When two QT‑prolonging agents (fluoxetine + trazodone) are prescribed together, a baseline ECG with QTc calculation is mandatory [13][14]
QTc ≥ 500 ms or an increase > 60–70 ms from baseline defines high risk for torsades de pointes and requires immediate drug discontinuation and continuous cardiac monitoring [13][14]

3. Baseline Cardiac Assessment (Pre‑treatment)

Obtain a 12‑lead ECG with QTc measurement before initiating the fluoxetine + trazodone regimen [13][14]
Check serum electrolytes and correct abnormalities before therapy: potassium > 4.0 mmol/L (optimally 4.5–5.0), magnesium > 2.0 mg/dL, calcium within normal range [13][14]
Screen all concurrent medications using crediblemeds.org to identify additional QT‑prolonging agents (e.g., macrolides, fluoroquinolones, antiarrhythmics, antiemetics) [13][14]

4. Risk Stratification

High‑risk patients – female sex, age > 60 years, structural heart disease, baseline QTc > 480 ms, concurrent diuretic use, or renal impairment – require more intensive monitoring [13][14]
If baseline QTc ≥ 500 ms or > 480 ms with risk factors, do not start the fluoxetine + trazodone combination; instead substitute fluoxetine with sertraline or paroxetine and replace trazodone with mirtazapine or low‑dose quetiapine [13][14]

5. Dose Optimization & Follow‑up Monitoring

Repeat ECG at 1 week and 2 weeks after therapy initiation and after any dose adjustment of either drug [13][14]
Discontinue the regimen immediately if QTc exceeds 500 ms or rises > 60–70 ms from baseline [13][14]
Monitor electrolytes every 2–4 weeks during the first 3 months, especially in patients on diuretics or with renal impairment [13][14]

6. Patient Education

Instruct patients to report palpitations, dizziness, syncope, or presyncope promptly, as these may signal ventricular arrhythmias [15][13]

7. Safer Alternative Strategies

Replace fluoxetine with sertraline (50–200 mg daily) or paroxetine (20–50 mg daily); both have negligible QT‑prolongation potential [13][14]
Replace trazodone with mirtazapine (7.5–30 mg at bedtime) or low‑dose quetiapine (25–100 mg at bedtime); these agents have lower hERG affinity and minimal QT risk [13][14]

8. Clinical Pitfalls to Avoid

Do not assume all SSRIs have equivalent cardiac safety; citalopram and escitalopram carry the highest QT risk, whereas sertraline and paroxetine are essentially negligible [13][14]
Do not overlook trazodone’s hERG inhibition; it can prolong QT at clinically relevant concentrations [13][14]
Do not add multiple QT‑prolonging agents without checking crediblemeds.org [13][14]
Do not ignore electrolyte abnormalities; hypokalemia and hypomagnesemia are common contributors to acquired long‑QT syndrome and must be corrected before attributing QT prolongation to medications [13][14]

Initial Evaluation and Management of QT Prolongation in Men

Immediate Assessment

Measure the QT interval with the tangent method in lead II or V5, excluding U‑waves, to obtain an accurate QTc. 16
In adult males, a QTc > 450 ms is considered prolonged; a QTc ≥ 500 ms signals high risk for torsades de pointes and mandates urgent intervention. 16
Perform a comprehensive medication review using crediblemeds.org to identify all QT‑prolonging agents (e.g., macrolide/fluoroquinolone antibiotics, antipsychotics such as haloperidol, antidepressants like citalopram, antiarrhythmics such as sotalol, antiemetics such as ondansetron, methadone). 17, 18, 19
Obtain serum potassium, magnesium, and calcium levels immediately, as abnormalities are the most common reversible contributors to acquired LQTS. 17
Screen for additional reversible factors (bradycardia, hypothyroidism, hypothermia, recent cardiac arrest) that can prolong the QT interval. 17

Risk Stratification

High‑Risk Features (require immediate action)

QTc ≥ 500 ms or an increase of > 60–70 ms from baseline obliges immediate cessation of QT‑prolonging drugs and continuous telemetry monitoring. 17, 18
A history of unexplained syncope triggered by exercise, swimming, or sudden loud noises raises suspicion for congenital LQTS. 20, 18, 19
A family history of sudden unexplained death or known LQTS further supports an inherited etiology. 20, 18

Moderate‑Risk Features

QTc 450–499 ms without syncope or a positive family history may permit continuation of essential QT‑prolonging medication provided electrolytes are normal and close ECG monitoring is instituted. 18

Acute Management Algorithm (QTc ≥ 500 ms or symptomatic)

Post‑Acute Evaluation

Repeat the ECG after five half‑lives of the discontinued drug and after electrolyte normalization. 18
If the QTc normalizes to < 450 ms, the diagnosis is acquired LQTS; genetic testing is not required. 18
If the QTc remains > 480 ms despite correction, suspect congenital LQTS and refer the patient to an inherited‑arrhythmia clinic. 20, 18, 19

Distinguishing Acquired from Congenital LQTS

Acquired LQTS clues – recent start of a QT‑prolonging drug, presence of electrolyte disturbances, and QTc normalization after drug cessation and electrolyte correction. 17, 18

Congenital LQTS clues – syncope precipitated by exercise (LQT1) or loud noises (LQT2), family history of sudden death < 40 years, persistent QTc > 480 ms after eliminating reversible causes, and characteristic T‑wave morphologies (broad‑based in LQT1, low‑amplitude notched in LQT2). 20, 19

Specialized Testing for Suspected Congenital LQTS

Exercise stress test (“rule‑out LQTS” protocol): obtain 12‑lead ECGs at 1‑minute intervals during exercise, a standing ECG, and a 4‑minute post‑exercise recovery ECG. 20
- LQT1 – QTc lengthens at peak exercise and stays prolonged during recovery.
- LQT2 – QTc may normalize at peak but becomes markedly prolonged (> 440 ms) during the 4–5 minute recovery phase.
- Normal response – QTc shortens at peak exercise and gradually returns to baseline.
Genetic testing: robust evidence exists only for KCNQ1 (LQT1), KCNH2 (LQT2), and SCN5A (LQT3); testing for the remaining 14 genes has weaker support. Testing should follow thorough phenotyping and not precede it. A pathogenic variant alone does not confirm disease without a compatible phenotype, but a first‑degree relative who carries a proven pathogenic variant (types 1‑3) should be managed as having congenital LQTS even if their QTc is normal. 20

Long‑Term Management

Acquired LQTS

Permanently avoid all QT‑prolonging drugs; provide patients with access to crediblemeds.org (website and smartphone app). 18, 19

Congenital LQTS

Beta‑blocker therapy:
- Nadolol 1–1.5 mg/kg once daily is preferred for high‑risk patients (QTc ≥ 500 ms or prior syncope/cardiac arrest). 20, 19
- Bisoprolol may be used in lower‑risk patients (QTc < 500 ms, no prior events) for better tolerability. 20, 19
- Non‑selective agents (nadolol, propranolol) provide superior protection compared with β1‑selective agents (atenolol, metoprolol). 20, 19
Lifelong avoidance of QT‑prolonging medications remains essential even while on beta‑blockers; drug exposure and non‑adherence are the primary causes of breakthrough events. 18, 19
Genotype‑specific lifestyle modifications: avoid swimming and vigorous exercise in LQT1; avoid sudden loud noises (e.g., alarm clocks, doorbells) in LQT2. 18, 19
Refer all suspected or confirmed congenital LQTS patients to an inherited‑arrhythmia clinic (e.g., www.heartsinrhythm.ca in Canada or www.sads.org internationally). 20, 19

Critical Pitfalls to Avoid

Do not assume QT prolongation is benign in men; a QTc > 450 ms warrants full evaluation. 16
Do not overlook “innocuous” QT‑prolonging medications such as macrolide antibiotics, fluoroquinolones, and common antidepressants. 17, 19
Do not use amiodarone or procainamide for ventricular arrhythmias when the QT is prolonged; they exacerbate torsades de pointes. 17
Do not diagnose congenital LQTS without first excluding all acquired causes, especially in patients > 50 years.
Do not forget to repeat the ECG after medication washout (five half‑lives) and electrolyte correction; normalization confirms an acquired etiology and obviates unnecessary genetic testing. 18
Do not add multiple QT‑prolonging agents without checking for interactions on crediblemeds.org. 19
Do not ignore electrolyte monitoring in patients on diuretics; hypokalemia and hypomagnesemia are the most common contributors to acquired LQTS. 17

QT‑Prolonging Medications and Associated Risks

Antiarrhythmic Agents

Antiarrhythmic drugs cause torsades de pointes (TdP) in approximately 1 %–10 % of treated patients, making them the medication class with the highest TdP incidence. (Evidence from clinical observations) 21
Class IA antiarrhythmics (e.g., quinidine, disopyramide, procainamide) block both sodium and potassium channels, leading to a significant prolongation of the QT interval. (Pharmacologic studies) 21
Class III antiarrhythmics (e.g., sotalol, dofetilide, ibutilide) selectively block potassium channels and have a well‑documented TdP incidence demonstrated in clinical trial data. (Randomized trial evidence) 21
Quinidine exhibits a paradoxical dose‑response: TdP frequently occurs at low plasma concentrations, whereas higher concentrations blunt QT prolongation through additional sodium‑channel blockade. (Case‑series analysis) 21

Antipsychotic Medications

Haloperidol has multiple published case reports confirming it can induce TdP in patients receiving the drug. (Case‑report level) 21
Thioridazine was withdrawn from the market because of its high TdP risk, underscoring the severe pro‑arrhythmic potential of certain antipsychotics. (Regulatory outcome) 21

Opioid Analgesics

Methadone requires a baseline ECG and repeat ECG after each dose adjustment due to its well‑documented association with TdP. (Prospective monitoring data) 21

Risk Stratification by Drug Potency

High‑risk drugs (methadone, haloperidol, antiarrhythmics) can increase TdP risk even in patients without additional risk factors. (Observational cohort) 21
Low‑risk drugs such as moxifloxacin generally precipitate TdP only when additional risk factors (e.g., electrolyte disturbances) are present. (Retrospective analysis) 21

Dose‑Dependent Effects

For virtually all QT‑prolonging medications, the risk of TdP rises with increasing plasma drug concentration, except for quinidine, which shows the opposite pattern at higher concentrations. (Pharmacokinetic‑risk modeling) 21
Drug‑drug interactions that inhibit metabolism—illustrated by CYP3A4 inhibition with terfenadine—can dramatically elevate QT risk by raising plasma drug levels. (Interaction studies) 21

Mechanistic Basis of QT Prolongation

The majority of QT‑prolonging drugs block the rapid component of the delayed rectifier potassium current (I_Kr), the key current responsible for cardiac repolarization. (Electrophysiologic investigations) 21
I_Kr inhibition is an extremely common pharmacologic effect, explaining why many structurally diverse agents prolong the QT interval. (Mechanistic review) 21

Management of QT‑Prolongation Risks in Methadone Therapy

Risk‑Factor Assessment

The American Heart Association (Circulation) recommends screening all patients receiving methadone for additional QT‑prolongation risk factors—including female sex, age > 60 years, structural heart disease, bradycardia, diuretic use, renal or hepatic impairment, and family history of sudden cardiac death—before initiating therapy. 22

Electrolyte Monitoring and Correction

The guideline advises that electrolyte abnormalities (hypokalemia and hypomagnesemia) are the most common contributors to methadone‑induced QT prolongation; therefore, serum potassium and magnesium should be routinely monitored and corrected to > 4.5 mmol/L and > 2.0 mg/dL, respectively. 22
In patients with QTc ≥ 500 ms, urgent correction of electrolytes is required, including administration of intravenous magnesium sulfate 2 g even when serum magnesium is within normal limits. 22

Management of Torsades de Pointes (TdP)

If torsades de pointes occurs in a methadone‑treated patient, immediate treatment should include intravenous magnesium, correction of bradycardia with temporary pacing or isoproterenol, and avoidance of amiodarone or procainamide, as these agents further prolong the QT interval. 22

Avoidance of Pro‑arrhythmic Medications

The guideline cautions against the use of amiodarone or procainamide for ventricular arrhythmias in the setting of a prolonged QT interval because they exacerbate torsades de pointes. 22

QT Prolongation Risk and Management of Metoclopramide (Reglan)

Evidence of QT Prolongation

Metoclopramide (Reglan) can prolong the QT interval and has been documented to cause torsades de pointes; it is considered a lower‑risk antiemetic relative to ondansetron or droperidol. 23

Guideline Recommendations (Canadian Cardiovascular Society, 2023)

The 2023 Canadian Cardiovascular Society guidelines classify antiemetics, including metoclopramide, as capable of QT prolongation and identify aprepitant and dexamethasone as low‑risk alternatives for patients susceptible to QT‑related arrhythmias, implicitly placing metoclopramide in a higher‑risk tier. 23

ECG Monitoring Recommendations

Obtain a baseline ECG with QTc measurement before administering metoclopramide when any of the following are present: severe electrolyte disturbance, concurrent use of another QT‑prolonging drug, multiple risk factors (female sex, age > 60 yr, structural heart disease, bradycardia, diuretic use, renal impairment), or baseline QTc > 480 ms or known congenital long‑QT syndrome. 23
Routine ECG monitoring is not required for otherwise healthy individuals without additional risk factors. 23

Medication Review and Interaction Checks

Prior to prescribing metoclopramide, review all concurrent medications using crediblemeds.org (or an equivalent drug‑interaction database) to identify additional QT‑prolonging agents. 23
Never add multiple QT‑prolonging agents without first checking for interactions on crediblemeds.org. 23

Alternative Antiemetics for High‑Risk Situations

When a patient’s QTc is ≥ 500 ms or multiple risk factors are present, substitute metoclopramide with aprepitant (NK₁‑receptor antagonist) or dexamethasone, both of which have no QT‑prolonging potential. 23

Guideline Recommendations for Prolonged QTc Interval Management

Immediate Risk Stratification

QTc ≥ 500 ms or an increase > 60–70 ms from baseline defines a high‑risk state for torsades de pointes and mandates urgent telemetry monitoring or ICU admission. 24
QTc 450–499 ms in men or 460–499 ms in women without syncope or a family history of sudden death may allow continuation of essential QT‑prolonging drugs, provided that ECGs are closely monitored and electrolytes remain normal. 24

Distinguishing Acquired from Congenital Long‑QT Syndrome

When QTc remains > 480 ms after drug wash‑out and electrolyte correction, congenital long‑QT syndrome should be suspected and the patient referred to an inherited‑arrhythmia clinic. 24

Management of Confirmed Congenital Long‑QT Syndrome

High‑Risk Patients (QTc ≥ 500 ms or prior syncope/cardiac arrest)

Nadolol 1–1.5 mg/kg once daily is the preferred beta‑blocker.
Lifelong avoidance of all QT‑prolonging medications is required.
Genotype‑specific lifestyle modifications (e.g., avoid swimming/vigorous exercise in LQT1; avoid sudden loud noises in LQT2). 24

Lower‑Risk Patients (QTc < 500 ms, no prior events)

Bisoprolol may be used for better tolerability.
Strict avoidance of QT‑prolonging drugs remains essential. 24
Beta‑blocker therapy should be continued perioperatively; abrupt discontinuation markedly increases breakthrough arrhythmic events. 24

Perioperative Considerations for Known Congenital LQTS

Avoid volatile anesthetic sevoflurane and the muscle relaxant succinylcholine.
Maintain heart rate > 70 bpm; treat bradycardia with temporary pacing rather than atropine. 24

Pregnancy Considerations

Continuation of beta‑blocker therapy is generally recommended for pregnant patients with congenital LQTS, with specialist consultation to balance fetal safety. 24

Doxycycline and QT Interval: Evidence from ACC/AHA Statement

Guideline Statements

The 2020 American College of Cardiology/American Heart Association statement on COVID‑19 drug interactions discusses the QT‑prolonging effects of azithromycin but does not mention doxycycline as a cardiac safety concern, indicating that doxycycline is not considered a QT‑prolonging antibiotic in this guideline. 25

Management of Extreme QTc Prolongation (QTc ≥ 596 ms)

Emergency Stabilization

Immediate discontinuation of every QT‑prolonging medication (including macrolide and fluoroquinolone antibiotics, certain antidepressants, antipsychotics, antiarrhythmics, antiemetics, and methadone) is required to halt further QT lengthening. 26
Use crediblemeds.org (or its app) to identify all prescription, over‑the‑counter, and supplement agents that can prolong the QT interval. 26
Admit the patient to a telemetry‑capable unit or ICU for continuous ECG monitoring; a QTc ≥ 500 ms mandates this level of surveillance, and a QTc of 596 ms places the patient at extreme risk for torsades de pointes. [27][28]
Urgently correct electrolytes: aim for serum potassium > 4.5 mmol/L (optimally 4.5–5.0 mmol/L), magnesium > 2.0 mg/dL, and normalize calcium. 26
Recognize hypokalemia and hypomagnesemia as the most common reversible contributors to acquired long QT, especially in patients receiving diuretics. 26

Diagnostic Re‑evaluation After Stabilization

Repeat a 12‑lead ECG after five drug half‑lives and after electrolyte normalization; manual QTc measurement using the tangent method in lead II or V5 (excluding U‑waves) is mandatory because automated values are unreliable. [27][28]

If QTc Normalizes (< 480 ms)

Diagnose acquired long QT syndrome; genetic testing is not indicated.
Enforce permanent avoidance of all QT‑prolonging drugs and provide the patient with access to crediblemeds.org for ongoing reference. 26
Implement regular electrolyte monitoring, particularly in individuals on diuretics or with renal impairment. 26

If QTc Remains > 480 ms

Suspect congenital long QT syndrome and refer urgently to an inherited‑arrhythmia/cardiogenetics clinic. [27][28]
Obtain a detailed history for red‑flag features (exercise‑triggered syncope, swimming‑related events, sudden‑noise triggers, family sudden death < 40 y, seizure‑like episodes). [27][28]
Conduct exercise stress testing with serial 12‑lead ECGs (baseline, peak, 1‑min post‑exercise, standing ECG, and 4‑min recovery) to differentiate LQT1 (peak/recovery prolongation) from LQT2 (prolongation at 4–5 min recovery). [27][28]
Consider targeted genetic testing for KCNQ1 (LQT1), KCNH2 (LQT2), and SCN5A (LQT3) after thorough phenotyping. [27][28]

Treatment of Confirmed Congenital LQTS

High‑Risk Patients (QTc ≥ 500 ms or prior syncope/cardiac arrest)

Nadolol 1–1.5 mg/kg once daily is the preferred beta‑blocker, offering superior protection compared with β1‑selective agents (e.g., atenolol, metoprolol). [27][28]29
Lifelong avoidance of all QT‑prolonging medications remains essential even while on beta‑blocker therapy; drug exposure and non‑adherence are the primary causes of breakthrough events. [26][29]
Genotype‑specific lifestyle counseling: avoid swimming and vigorous exercise in LQT1; avoid sudden loud noises (alarms, doorbells) in LQT2. [29][30]

Lower‑Risk Patients (QTc < 500 ms, no prior events)

Bisoprolol may be used for better tolerability, although nadolol remains the preferred agent. [27][28]29
Strict avoidance of QT‑prolonging drugs continues to be mandatory. [27][28]

Amplifying Risk Factors for Acquired LQTS

Female sex, advanced age, and structural heart disease are the highest‑risk demographics for drug‑induced QT prolongation. 26
Diuretic therapy predisposes to hypokalemia and hypomagnesemia, the most frequent electrolyte triggers. 26
Renal or hepatic impairment increases drug accumulation and heightens QT‑prolongation risk. 26

Electrocardiographic Quality Assurance

Manual QTc verification using the tangent method is required; automated QTc measurements should not be relied upon when the baseline interval is abnormal. [27][31]

Medication Safety and Safer Alternatives

Antibiotics: substitute macrolides/fluoroquinolones with penicillins or cephalosporins, which carry negligible QT risk. 26
Antidepressants: replace citalopram/escitalopram with sertraline or paroxetine, which have minimal QT‑prolonging potential. 26
General principle: avoid “innocuous” QT‑prolonging agents (e.g., macrolides, fluoroquinolones, common antidepressants) and do not combine multiple QT‑prolonging drugs without checking for interactions on crediblemeds.org. 26

Laboratory Evaluation and Diagnostic Approach for Long QT Syndrome

Essential Laboratory Panel

Serum electrolytes (potassium, magnesium, calcium) are the primary laboratory tests for evaluating long QT syndrome because electrolyte abnormalities—especially hypokalemia and hypomagnesemia—are the most common reversible contributors to acquired QT prolongation. 32
Serum potassium should be measured and corrected to > 4.0 mmol/L (optimally 4.5–5.0 mmol/L); hypokalemia is a leading cause of acquired QT prolongation. 32
Serum magnesium should be corrected to > 2.0 mg/dL; hypomagnesemia frequently co‑exists with hypokalemia, particularly in individuals receiving diuretics. 32
Serum calcium must be normalized because hypocalcemia can prolong the QT interval. 32
Renal function (creatinine, eGFR) should be assessed, as renal impairment increases accumulation of QT‑prolonging medications and heightens arrhythmia risk. 33
Thyroid function tests (TSH, free T4) are warranted when hypothyroidism is suspected, since hypothyroidism can prolong the QT interval. 34

Determining Acquired vs. Congenital Long QT

If the QTc shortens to < 450 ms in males or < 460 ms in females after electrolyte correction and discontinuation of QT‑prolonging drugs, the condition is classified as acquired long QT syndrome and genetic testing is not required. 32
Permanent avoidance of QT‑prolonging medications and regular electrolyte monitoring—especially in individuals on diuretics—are mandatory to prevent recurrence of acquired QT prolongation. 33
When the QTc remains > 480 ms after correction of all reversible causes, congenital long QT syndrome should be suspected and the patient referred to an inherited arrhythmia clinic. 34

Genetic Evaluation

Genetic testing for the major LQTS genes (KCNQ1 [LQT1], KCNH2 [LQT2], SCN5A [LQT3]) can be considered after thorough clinical phenotyping. 35
Approximately 15–20 % of individuals with clinically diagnosed congenital LQTS have no identifiable pathogenic variant and are termed “genetically elusive.” 34

High‑Risk Populations Requiring Intensive Monitoring

Female sex, advanced age, and the presence of structural heart disease are the highest‑risk demographics for drug‑induced QT prolongation. 34
Individuals receiving diuretics need serial electrolyte monitoring because they are prone to hypokalemia and hypomagnesemia. 33
Patients with renal or hepatic impairment require regular monitoring of electrolytes and renal function due to the increased risk of drug accumulation. 33

Medication‑Related Pitfalls and Monitoring Strategies

Many commonly used agents—such as macrolide antibiotics, fluoroquinolones, and certain antidepressants (e.g., citalopram, escitalopram)—can induce QT prolongation and should be reviewed carefully. 33
Clinicians should not assume a QT‑prolonged ECG is congenital without first excluding all acquired causes, particularly in individuals older than 50 years. 34
An ECG should be repeated after a medication washout period (approximately five drug half‑lives) and after electrolyte correction; normalization confirms an acquired etiology and avoids unnecessary genetic testing. 32

Guideline Recommendations on Diphenhydramine‑Related QT Prolongation

Guideline Classification

The 2023 Canadian Cardiovascular Society guideline and the 2010 American Heart Association/American College of Cardiology statement do not list diphenhydramine among high‑risk QT‑prolonging medications. [36][37]
According to the 2010 AHA/ACC statement, drugs classified as high‑risk for torsades de pointes (e.g., methadone, haloperidol, class Ia/III antiarrhythmics, certain macrolides and fluoroquinolones) can precipitate torsades even without additional risk factors, whereas low‑risk agents (e.g., moxifloxacin) generally require co‑existing electrolyte disturbances or other vulnerabilities. 36

Therapeutic Dosing Recommendations

Routine electrocardiographic monitoring is not required when prescribing standard diphenhydramine doses (25–50 mg) to otherwise healthy adults without additional QT‑prolongation risk factors. Canadian Cardiovascular Society recommendation. 37
Caution is advised in high‑risk populations—including female sex, advanced age, structural heart disease, baseline QTc > 480 ms, concurrent use of other QT‑prolonging drugs, electrolyte abnormalities (hypokalemia, hypomagnesemia, hypocalcemia), renal impairment, or diuretic therapy. Canadian Cardiovascular Society recommendation. 37

Overdose or Supratherapeutic Exposure Management

In overdose settings, diphenhydramine should be immediately discontinued and continuous cardiac telemetry initiated when the QTc ≥ 500 ms or the patient exhibits palpitations, syncope, or presyncope. Canadian Cardiovascular Society recommendation. 37
Electrolyte abnormalities must be corrected urgently: target serum potassium > 4.5 mmol/L, magnesium > 2.0 mg/dL, and normalize calcium levels. Canadian Cardiovascular Society recommendation. 37

Drug‑Interaction Screening & Monitoring

Clinicians should use crediblemeds.org (or its mobile app) to identify all concurrent QT‑prolonging medications before prescribing diphenhydramine to patients with multiple risk factors. Canadian Cardiovascular Society recommendation. 37
Never combine multiple QT‑prolonging agents without checking for interactions, especially in patients with baseline QTc > 480 ms or structural heart disease. Canadian Cardiovascular Society recommendation. 37
Electrolyte monitoring is essential in patients receiving diuretics or those with renal impairment because hypokalemia and hypomagnesemia are the most common reversible contributors to acquired long QT syndrome. Canadian Cardiovascular Society recommendation. 37

Clinical Decision Algorithm (Key Points)

Therapeutic dose in low‑risk patient → No baseline ECG required; proceed with standard dosing. Canadian Cardiovascular Society recommendation. 37
Therapeutic dose in high‑risk patient (baseline QTc > 480 ms, structural heart disease, multiple QT‑prolonging drugs, electrolyte disturbances) → Obtain baseline ECG, correct electrolytes, and consider an alternative non‑sedating antihistamine (e.g., cetirizine, loratadine). Canadian Cardiovascular Society recommendation. 37
Overdose or supratherapeutic exposure → Discontinue diphenhydramine, initiate telemetry, correct electrolytes, repeat ECG after five half‑lives (≈ 24–48 h), and treat any torsades de pointes with intravenous magnesium sulfate 2 g. Canadian Cardiovascular Society recommendation. 37
Persistent QTc > 480 ms after correction → Suspect congenital long QT syndrome and refer to an inherited arrhythmia clinic. Canadian Cardiovascular Society recommendation. 37

Management of Elevated Natriuretic Peptides and Prolonged QTc Interval

QTc Interval Interpretation

The upper normal limits for the corrected QT interval are < 450 ms in men and < 460 ms in women. [Canadian Cardiovascular Society] 38
A QTc ≥ 480 ms is considered abnormal and warrants further evaluation. [Canadian Cardiovascular Society] 38
QTc ≥ 500 ms or an increase of > 60–70 ms from baseline defines a high‑risk state for torsades de pointes. [Canadian Cardiovascular Society] [38][39]

Prognostic Significance of Natriuretic Peptides

In patients with heart failure, an elevated BNP/NT‑proBNP at presentation predicts both short‑ and long‑term mortality, with a nearly linear rise in in‑hospital death across BNP quartiles. [American Heart Association] 40
A predischarge BNP measurement is the strongest single predictor of 1‑year mortality or heart‑failure hospitalization. [American Heart Association] 40

Evaluation of Acquired Long QT Syndrome

Reversible Medication‑Related Causes

The majority of acquired QT prolongation is due to medications; common offenders include:
- Antibiotics – fluoroquinolones, macrolides (especially erythromycin)
- Antidepressants – citalopram, escitalopram
- Antipsychotics – haloperidol, ziprasidone, iloperidone
- Antiarrhythmics – sotalol, dofetilide, amiodarone, procainamide
- Antiemetics – ondansetron, droperidol
- Methadone

Electrolyte Management

Target serum potassium > 4.5 mmol/L (optimally 4.5–5.0 mmol/L). [Canadian Cardiovascular Society] [38][39]
Target serum magnesium > 2.0 mg/dL. [Canadian Cardiovascular Society] [38][39]
Calcium should be normalized. [Canadian Cardiovascular Society] [38][39]
Hypokalemia and hypomagnesemia are the most frequent reversible contributors, especially in patients receiving diuretics. [Canadian Cardiovascular Society] [38][39]

Additional Reversible Factors

Bradycardia (sinus bradycardia or AV block)
Thyroid dysfunction (hypo‑ or hyper‑thyroidism)
Hypothermia

Risk Stratification and Monitoring

Structural heart disease markedly increases the risk of drug‑induced arrhythmias and identifies a high‑risk demographic for acquired long QT. [Canadian Cardiovascular Society] [38][39]
QTc ≥ 500 ms:
- Immediately discontinue all QT‑prolonging drugs. [Canadian Cardiovascular Society] [38][39]
- Initiate continuous cardiac telemetry or ICU admission. [Canadian Cardiovascular Society] [38][39]
- Urgently correct electrolytes. [Canadian Cardiovascular Society] [38][39]
QTc 450–499 ms in men or 460–499 ms in women:
- Close ECG monitoring is required when multiple risk factors are present (female sex, age > 60 years, structural heart disease, diuretic use, renal impairment). [Canadian Cardiovascular Society] [38][39]
- Continuation of essential QT‑prolonging medication may be considered only with close monitoring and normal electrolytes. [Canadian Cardiovascular Society] 38

Therapeutic Recommendations

Avoid amiodarone and procainamide in patients with QT prolongation, as they further lengthen the QT interval and can precipitate torsades de pointes. [Canadian Cardiovascular Society] [38][39]

Long‑Term Surveillance

Serial BNP/NT‑proBNP measurements should be performed to monitor heart‑failure progression and risk stratification. [American Heart Association] 40

Clinical Pitfalls (Do‑Not Statements)

Do not assume QTc prolongation is benign; a QTc > 450 ms in men or > 460 ms in women mandates a full evaluation. [Canadian Cardiovascular Society] 38
Do not overlook “innocuous” QT‑prolonging drugs such as macrolide antibiotics, fluoroquinolones, and common antidepressants. [Canadian Cardiovascular Society] 38
Do not use amiodarone or procainamide for ventricular arrhythmias when the QT interval is already prolonged. [Canadian Cardiovascular Society] [38][39]
Do not ignore electrolyte monitoring in patients on diuretics; hypokalemia and hypomagnesemia are the most common contributors to acquired long QT. [Canadian Cardiovascular Society] [38][39]

QT‑Interval Prolongation: Evidence‑Based Key Points

Medication‑Related Causes

Antiarrhythmic drugs (e.g., sotalol, dofetilide, ibutilide, amiodarone, procainamide, quinidine, disopyramide) precipitate torsades de pointes in ≈ 1–10 % of treated patients, making this class the highest‑risk for QT prolongation. 41
Fluoroquinolone and macrolide antibiotics (especially ciprofloxacin and erythromycin) carry a significant QT‑prolonging risk, whereas penicillins and cephalosporins are essentially benign. 41
High‑risk antipsychotics (haloperidol, ziprasidone, iloperidone, amisulpride, thioridazine, chlorpromazine) markedly increase QT, while agents such as aripiprazole, clozapine, and lurasidone have negligible effect. 41
SSRIs with the greatest QT impact are citalopram and escitalopram; sertraline and paroxetine pose minimal risk. 41
Methadone requires a baseline ECG and repeat ECG after dose adjustments because of a well‑documented association with torsades de pointes. 41
Other agents known to prolong QT include chloroquine, hydroxychloroquine, triptans, and certain antifungals (fluconazole, ketoconazole). 41

Electrolyte Abnormalities

Hypokalemia is the single most frequent electrolyte trigger of acquired QT prolongation; target serum potassium > 4.5 mmol/L (optimally 4.5–5.0 mmol/L). 41
Hypomagnesemia frequently co‑exists with hypokalemia and should be corrected to serum magnesium > 2.0 mg/dL. 41
Hypocalcemia also lengthens QT and should be normalized when present. 41

Cardiac & Hemodynamic Factors

Bradycardia (sinus bradycardia or AV block) independently prolongs QT regardless of other contributors. 41
Structural heart disease (left‑ventricular dysfunction, hypertrophy, congestive heart failure, valvular disease) markedly heightens the risk of drug‑induced arrhythmias. 41
Hypothermia directly prolongs ventricular repolarization. 41

Demographic & Patient‑Specific Risk Factors

Female sex is the strongest demographic predictor of drug‑induced QT prolongation. 41
Age > 60 years amplifies QT‑prolonging risk from medications and electrolyte disturbances. 41
Diuretic therapy predisposes to hypokalemia and hypomagnesemia, the most common electrolyte triggers. 41
Renal or hepatic impairment increases drug accumulation, raising QT‑prolongation risk. 41
Baseline QTc > 480 ms or a known congenital LQTS dramatically raises the likelihood of torsades de pointes with any additional QT‑prolonging exposure. 41
Concurrent use of multiple QT‑prolonging drugs should be avoided; clinicians should verify interactions via crediblemeds.org. 41
CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) can dramatically increase QT risk by elevating plasma concentrations of QT‑prolonging agents. 41

Congenital Long‑QT Syndrome (LQTS) Considerations

Diagnostic threshold: Suspect congenital LQTS when QTc remains > 480 ms after discontinuation of all QT‑prolonging drugs and correction of electrolytes. 41
Red‑flag clinical features include unexplained syncope triggered by exercise (LQT1), swimming (LQT1), or loud noises (LQT2); family history of sudden unexplained death < 40 years; seizure‑like episodes; and presentation at a young age. 41

Management Pitfalls to Avoid

Do not overlook electrolyte monitoring in patients with gastrointestinal losses (e.g., GVHD‑related diarrhea); hypokalemia and hypomagnesemia are the most common reversible contributors. 41
Do not assume all SSRIs carry equal QT risk; prioritize avoidance of citalopram and escitalopram when QT is prolonged. 41
Avoid amiodarone or procainamide in patients with an already prolonged QT interval, as they exacerbate torsades de pointes. 41
Do not dismiss “innocuous” QT‑prolonging drugs such as macrolide antibiotics, fluoroquinolones, and common antidepressants. 41
Repeat ECG after medication washout (five drug half‑lives) and after electrolyte correction; normalization confirms an acquired etiology and obviates unnecessary genetic testing. 41

QTc Prolongation Risks of Psychotropic Medications

Antipsychotic Medications

Ziprasidone, amisulpride, haloperidol, thioridazine, and chlorpromazine are identified as the highest‑risk antipsychotics for drug‑induced QTc prolongation in patients receiving psychotropic therapy. 42
Haloperidol has multiple documented cases of torsades de pointes, especially when administered intravenously to medically ill patients, indicating a high arrhythmic risk. 42
Thioridazine was withdrawn from the market because of severe QTc prolongation and a high incidence of torsades de pointes, making it the most dangerous typical antipsychotic from a cardiac standpoint. 42

Antidepressant Medications

Citalopram produces greater QTc prolongation than any other selective serotonin reuptake inhibitor (SSRI); consequently, regulatory agencies (FDA and EMA) limit its maximum dose to 40 mg daily (20 mg in patients > 60 years) due to dose‑dependent QTc effects. [42][43]
Escitalopram also causes significant QTc prolongation, though less than citalopram, and is subject to the same regulatory dose restrictions (maximum 20 mg daily, 10 mg in elderly patients). [42][43]
Tricyclic antidepressants (TCAs) as a class prolong QTc and delay atrioventricular‑node conduction; amitriptyline and maprotiline are specifically linked to torsades de pointes cases and an odds ratio of 1.69 for cardiac arrest. [42][43]

Opioid Analgesics

Management of Severely Prolonged QTc (≥ 500 ms)

QTc Thresholds and Associated Risk

A QTc < 450 ms in men and < 460 ms in women is considered normal; a QTc ≥ 500 ms signals extreme arrhythmic risk and mandates urgent intervention. 44
A QTc of 528 ms exceeds the 500 ms critical threshold, indicating an imminent risk for life‑threatening ventricular arrhythmias. [44][45]
The probability of torsades de pointes rises nearly linearly once the QTc surpasses 500 ms. 44

Immediate Assessment and Monitoring

Admit the patient to a telemetry‑capable unit or intensive care setting for continuous ECG monitoring; QTc ≥ 500 ms requires this level of surveillance. [44][45]
Evaluate for bradycardia (sinus bradycardia or AV block), which independently prolongs the QT interval. 44
Obtain an urgent echocardiogram to assess for structural heart disease (e.g., left‑ventricular dysfunction, valvular pathology). 44
Screen for additional reversible contributors such as hypothyroidism, hypothermia, recent cardiac arrest, and renal or hepatic impairment. 44

Reversible Causes – Medication Review

Immediately discontinue all QT‑prolonging medications; do not await further testing. [44][46]
Use the crediblemeds.org resource (website or smartphone app) to identify every prescription, over‑the‑counter, and supplement agent that can prolong QT. [44][46]
Common QT‑prolonging drug categories include:
- Antibiotics – fluoroquinolones (e.g., ciprofloxacin, levofloxacin) and macrolides (e.g., erythromycin, azithromycin).
- Antidepressants – citalopram, escitalopram (highest SSRI risk).
- Antipsychotics – haloperidol, ziprasidone, iloperidone, chlorpromazine.
- Antiarrhythmics – sotalol, dofetilide, amiodarone, procainamide.
- Antiemetics – ondansetron, droperidol, metoclopramide.
- Opioids – methadone.
- Other agents – chloroquine, hydroxychloroquine, certain antifungals. 44

Reversible Causes – Electrolyte Management

Promptly measure serum electrolytes; hypokalemia and hypomagnesemia are the most frequent contributors to acquired QT prolongation. [44][45]
Target serum potassium > 4.5 mmol/L (optimally 4.5–5.0 mmol/L). 44
Target serum magnesium > 2.0 mg/dL; hypomagnesemia often coexists with hypokalemia, especially in patients on diuretics. 44
Correct calcium abnormalities if present, as hypocalcemia also lengthens QT. 44

Post‑Stabilization Diagnostic Pathway

After medication washout (five drug half‑lives) and electrolyte correction, repeat the ECG; normalization confirms an acquired long‑QT etiology. 44
Genetic testing is not required when the QTc normalizes after removal of reversible causes. 44
Provide the patient with ongoing access to crediblemeds.org and enforce permanent avoidance of QT‑prolonging drugs. [44][46]
Institute regular electrolyte monitoring, particularly in individuals on diuretics or with renal impairment. 44

Screening for Congenital Long QT Syndrome

If the QTc remains > 480 ms after correction, suspect congenital LQTS and refer urgently to an inherited arrhythmia/cardiogenetics clinic. [44][45]
Red‑flag clinical features suggesting congenital LQTS include:
- Unexplained syncope triggered by exercise or swimming (LQT1).
- Syncope precipitated by sudden loud noises (LQT2).
- Family history of sudden unexplained death < 40 years.
- Seizure‑like episodes that may represent misdiagnosed cardiac events.
- Presentation at a young age with genotype‑specific triggers. 44
Genetic testing for KCNQ1 (LQT1), KCNH2 (LQT2), and SCN5A (LQT3) should be performed only after thorough phenotyping. 44

Management of Confirmed Congenital LQTS

High‑Risk Patients (QTc ≥ 500 ms or prior syncope/cardiac arrest)

Nadolol 1–1.5 mg/kg once daily is the preferred beta‑blocker, offering superior protection compared with β1‑selective agents. [44][46]
Lifelong avoidance of all QT‑prolonging medications remains essential even while on beta‑blocker therapy; drug exposure and non‑adherence are the primary causes of breakthrough events. [44][46]
Genotype‑specific lifestyle modifications:
- LQT1 – avoid swimming and vigorous exercise.
- LQT2 – avoid sudden loud noises (e.g., alarm clocks, doorbells). [44][46]

Lower‑Risk Patients (QTc < 500 ms, no prior events)

Bisoprolol may be used for better tolerability, although nadolol remains the preferred agent. 44
Strict avoidance of QT‑prolonging drugs continues to be mandatory. 44

Acute Treatment of Torsades de Pointes

Administer intravenous magnesium sulfate 2 g immediately, even if serum magnesium is within the normal range. 44
Correct bradycardia with temporary pacing or isoproterenol; avoid atropine in this setting. 44
Do not use amiodarone or procainamide for ventricular arrhythmias when the QT interval is prolonged, as they further lengthen QT and worsen torsades. [44][46]

Critical Pitfalls to Avoid

Do not assume a QTc of 528 ms is benign; it constitutes a medical emergency. [44][45]
Do not overlook “innocuous” QT‑prolonging agents such as macrolide antibiotics, fluoroquinolones, and common antidepressants. 44
Do not ignore electrolyte monitoring in patients on diuretics; hypokalemia and hypomagnesemia are the most common contributors to acquired LQTS. 44
Do not diagnose congenital LQTS without first excluding all acquired causes, especially in adult patients. 44
Always repeat the ECG after medication washout (five half‑lives) and electrolyte correction; normalization confirms an acquired etiology and avoids unnecessary genetic testing. 44
Never add multiple QT‑prolonging agents without checking for interactions on crediblemeds.org. [44][46]

Management of Severely Prolonged QTc (≥ 500 ms)

QTc Thresholds and Associated Risk

A corrected QT interval ≥ 500 ms is considered severely abnormal, far exceeding the normal upper limits (< 450 ms for men, < 460 ms for women) and markedly increases the risk of torsades de pointes and sudden cardiac death【47】.
The likelihood of torsades de pointes rises in an almost linear fashion once the QTc surpasses 500 ms, making prompt intervention essential【47】.
Presence of a normal sinus rhythm does not protect against ventricular arrhythmias when the QTc is markedly prolonged【47】.

Immediate Stabilization Measures

Admit the patient to a telemetry‑capable unit or intensive care setting for continuous ECG monitoring without delay【47】.
Discontinue all QT‑prolonging medications immediately, including antibiotics (e.g., fluoroquinolones, macrolides), antidepressants (e.g., citalopram, escitalopram), antipsychotics (e.g., haloperidol, ziprasidone), antiarrhythmics (e.g., sotalol, dofetilide), antiemetics (e.g., ondansetron), opioids (e.g., methadone), and agents such as chloroquine or hydroxychloroquine【47】.
Use the crediblemeds.org resource (website or app) to identify any prescription, over‑the‑counter, or supplement agents that may prolong the QT interval【47】.

Electrolyte Optimization

Promptly measure serum potassium, magnesium, and calcium; correct abnormalities to target levels of potassium > 4.5 mmol/L (optimally 4.5–5.0 mmol/L) and magnesium > 2.0 mg/dL, and normalize calcium if low【47】.

Diagnostic Evaluation After Stabilization

After drug washout (five half‑lives) and electrolyte correction, repeat a 12‑lead ECG and perform manual QTc measurement (tangent method in lead II or V5, excluding U‑waves) because automated values are unreliable【48】.
If the QTc normalizes, the diagnosis is acquired long QT syndrome; genetic testing is not indicated【47】.
If the QTc remains > 480 ms despite correction, suspect congenital long QT syndrome and refer urgently to an inherited‑arrhythmia/cardiogenetics clinic【47】.

Assessment for Congenital LQTS

Obtain a detailed history for red‑flag features: exercise‑triggered syncope (suggestive of LQT1), syncope precipitated by sudden loud noises (suggestive of LQT2), family history of sudden unexplained death < 40 years, and seizure‑like episodes that may represent cardiac events【47】.
Perform exercise stress testing with serial ECGs (baseline, peak, 1‑min post‑exercise, standing, and 4‑min recovery) to differentiate LQT1 (peak/recovery prolongation) from LQT2 (prolongation during late recovery)【47】.
Consider targeted genetic testing for KCNQ1, KCNH2, and SCN5A after thorough phenotyping【47】.

Therapeutic Strategies for Confirmed Congenital LQTS

High‑risk patients (QTc ≥ 500 ms or prior syncope/cardiac arrest): use nadolol 1–1.5 mg/kg once daily as the preferred beta‑blocker, offering superior protection compared with β1‑selective agents such as atenolol or metoprolol【47】.
Low‑risk patients (QTc < 500 ms, no prior events): bisoprolol may be employed for better tolerability, although nadolol remains the preferred agent【47】.
Lifelong avoidance of all QT‑prolonging drugs is mandatory for both high‑ and low‑risk patients, with ongoing access to crediblemeds.org for medication checks【47】.
Provide genotype‑specific lifestyle counseling:
- LQT1 – avoid swimming and vigorous exercise【47】.
- LQT2 – avoid sudden loud noises (e.g., alarms, doorbells)【47】.

Acute Management of Torsades de Pointes (If It Occurs)

Administer intravenous magnesium sulfate 2 g immediately, even when serum magnesium is within the normal range【47】.
Correct bradycardia with temporary pacing or isoproterenol; avoid atropine in this setting【47】.
Do not use amiodarone or procainamide for ventricular arrhythmias when the QT interval is prolonged, as they can exacerbate torsades【47】.

Demographic and Clinical Modifiers of Risk

Female sex is the strongest demographic predictor of drug‑induced QT prolongation【47】.
Advanced age (> 60 years) amplifies the risk associated with QT‑prolonging medications and electrolyte disturbances【47】.
Structural heart disease (e.g., left‑ventricular dysfunction, hypertrophy, heart failure, valvular pathology) markedly heightens arrhythmic risk【47】.
Diuretic therapy predisposes to hypokalemia and hypomagnesemia, the most common reversible triggers of acquired QT prolongation【47】.
Renal or hepatic impairment increases drug accumulation, further elevating QT‑prolongation risk【47】.

Technical Considerations

Always repeat the ECG after medication washout and electrolyte correction; normalization confirms an acquired etiology and prevents unnecessary genetic testing【47】.
Manual QTc verification using the tangent method is required when baseline intervals are abnormal, as automated measurements are unreliable【48】.

QTc Prolongation Risk of Bupropion (Wellbutrin XL)

Guideline Classification

The 2023 Canadian Cardiovascular Society guideline on prolonged QT interval does not list bupropion among QT‑prolonging medications, which instead includes macrolides, fluoroquinolones, citalopram, escitalopram, haloperidol, ondansetron, methadone, and antiarrhythmics. 49
The 2014 European Society of Cardiology risk‑stratification framework for psychotropic drugs also omits bupropion from its QT‑risk categories, while explicitly naming tricyclic antidepressants, citalopram, and typical antipsychotics as higher‑risk agents. 50

Clinical Recommendations

For otherwise healthy adults receiving Wellbutrin XL 150 mg, baseline or follow‑up ECG monitoring for QTc prolongation is not required. 49
Routine ECG is not indicated when prescribing bupropion 150 mg to patients without additional cardiac risk factors (e.g., female sex, age > 60 years, structural heart disease, baseline QTc > 480 ms, concurrent QT‑prolonging drugs, electrolyte disturbances, or renal impairment). 51

Urgent Management of QTc ≥ 500 ms

Immediate Actions Before Cardiology Referral

Discontinue all QT‑prolonging medications immediately – including macrolide/fluoroquinolone antibiotics, certain antidepressants (e.g., citalopram, escitalopram), antipsychotics (haloperidol, ziprasidone), antiarrhythmics (sotalol, dofetilide, amiodarone), antiemetics (ondansetron, metoclopramide), and methadone. 52, 53, 54
Use crediblemeds.org to identify every prescription, over‑the‑counter, or supplement agent that can prolong the QT interval. 52
Correct electrolytes urgently – target serum potassium > 4.5 mmol/L (optimal 4.5–5.0 mmol/L), magnesium > 2.0 mg/dL, and normalize calcium; hypokalemia and hypomagnesemia are the most common reversible contributors to acquired QT prolongation. 52, 53
Monitor electrolytes serially in patients on diuretics, as they are prone to potassium and magnesium depletion. 52
Admit to a telemetry‑capable unit or ICU for continuous ECG surveillance; QTc ≥ 500 ms warrants this level of monitoring to detect torsades de pointes. 52, 53, 55

Diagnostic Pathway After Stabilization

Repeat a 12‑lead ECG after five drug half‑lives and electrolyte correction, measuring QTc manually with the tangent method in lead II or V5 (excluding U‑waves) because automated values are unreliable. 52, 53
If QTc normalizes (< 450 ms in men, < 460 ms in women) → diagnose acquired long QT syndrome; genetic testing is not indicated. 52, 53
If QTc normalizes, enforce permanent avoidance of all QT‑prolonging drugs and provide access to crediblemeds.org. 52
If QTc normalizes, implement regular electrolyte monitoring, especially in patients receiving diuretics. 52
If QTc remains > 480 ms despite correction, suspect congenital long QT syndrome and refer urgently to an inherited‑arrhythmia/cardiogenetics clinic. 52, 53, 54
Red‑flag history for congenital LQTS – exercise‑triggered syncope (LQT1), syncope with sudden loud noises (LQT2), family history of sudden unexplained death < 40 years, or seizure‑like episodes. 52, 53, 54
Exercise stress testing with serial ECGs (baseline, peak, 1‑min post‑exercise, standing, 4‑min recovery) helps differentiate LQT1 from LQT2. 52, 53
Consider genetic testing for KCNQ1 (LQT1), KCNH2 (LQT2), and SCN5A (LQT3) after thorough phenotyping. 52, 53

Risk Amplification Factors

Female sex, age > 60 years, and structural heart disease (e.g., left‑ventricular dysfunction, heart failure, valvular disease) markedly increase the risk of drug‑induced arrhythmias. 52, 55
Bradycardia, renal or hepatic impairment, and concurrent use of multiple QT‑prolonging drugs further elevate arrhythmic risk. 52, 55

Management of Confirmed Congenital LQTS

High‑Risk Patients (QTc ≥ 500 ms or prior syncope/cardiac arrest)

Nadolol 1–1.5 mg/kg once daily is the preferred beta‑blocker, offering superior protection compared with β1‑selective agents (atenolol, metoprolol). 53, 54
Lifelong avoidance of all QT‑prolonging medications remains essential even while on beta‑blockers; drug exposure and non‑adherence are the primary causes of breakthrough events. 53, 54
Genotype‑specific lifestyle modifications – avoid swimming/vigorous exercise in LQT1; avoid sudden loud noises (alarms, doorbells) in LQT2. 53, 54

Lower‑Risk Patients (QTc < 500 ms, no prior events)

Bisoprolol may be used for better tolerability, although nadolol remains the preferred agent. 53, 54
Strict avoidance of QT‑prolonging drugs continues to be mandatory. 53, 54